FONT-SIZE Plus   Neg

TONIX Closes PK Study On New Formulation Of TNX-102 For Fibromyalgia

Tonix Pharmaceuticals Holding Corp (TNXP.OB), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system or "CNS", said that it completed a pharmacokinetic or PK study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome or "FM".

The company noted that the study results support further development of TNX-102 as a product that can potentially deliver benefits similar to those observed in FM patients treated with very low dose cyclobenzaprine in the Company's dose-escalating Phase 2a study.

TONIX said that it is developing new formulations of cyclobenzaprine that are designed for bedtime use. The Company is investigating different technologies to improve the absorption of cyclobenzaprine. The technology applied in this study involves a mixture of cyclobenzaprine and lipids that the Company obtained from Lipocine, Inc. and is designated TNX-102 2.4 mg promicellar gelatin capsules, or gelcaps.

TONIX said that it is on track to initiate a pivotal efficacy study with the final formulation of TNX-102 in the first quarter of 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a sign that other retailers may be re-thinking their Thanksgiving hours, Staples will be closed for the day. Like Wal-Mart and others, Staples was open on Thanksgiving Day for the past two years. European Court of Justice in Luxembourg has canceled the international agreement between European Union and United States to handover digital information, such as web search histories and social media updates. The ruling will be a blow to tech giants Google, Microsoft, Facebook, Amazon, etc. Volkswagen Australia Wednesday confirmed that more than 91 thousand vehicles sold in Australia were fitted with emission cheating software. Volkswagen brand alone comes to 77,000 cars and 14,000 cars are Audis.
comments powered by Disqus
Follow RTT